UNIVERSE PHARMACEUTICALS INC (UPC)
KYG9442G1120 - Common Stock
UPC gets a fundamental rating of 1 out of 10. The analysis compared the fundamentals against 194 industry peers in the Pharmaceuticals industry. Both the profitability and financial health of UPC have multiple concerns. UPC is valued expensive and it does not seem to be growing.
1. Profitability
1.1 Basic Checks
In the past year UPC has reported negative net income.
In the past year UPC has reported a negative cash flow from operations.
The reported net income has been mixed in the past 5 years: UPC reported negative net income in multiple years.
The reported operating cash flow has been mixed in the past 5 years: UPC reported negative operating cash flow in multiple years.
1.2 Ratios
UPC has a Return On Assets (-37.53%) which is in line with its industry peers.
The Return On Equity of UPC (-69.36%) is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -37.53% | ||
| ROE | -69.36% | ||
| ROIC | N/A |
ROA(3y)-3.37%
ROA(5y)11.69%
ROE(3y)-5.07%
ROE(5y)16.43%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
UPC's Gross Margin of 28.27% is in line compared to the rest of the industry. UPC outperforms 54.17% of its industry peers.
In the last couple of years the Gross Margin of UPC has declined.
The Profit Margin and Operating Margin are not available for UPC so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 28.27% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-11.39%
GM growth 5Y-7.46%
2. Health
2.1 Basic Checks
UPC does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for UPC remains at a similar level compared to 1 year ago.
Compared to 5 years ago, UPC has more shares outstanding
Compared to 1 year ago, UPC has an improved debt to assets ratio.
2.2 Solvency
Based on the Altman-Z score of 0.57, we must say that UPC is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of UPC (0.57) is comparable to the rest of the industry.
A Debt/Equity ratio of 0.08 indicates that UPC is not too dependend on debt financing.
UPC has a Debt to Equity ratio (0.08) which is in line with its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.08 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 0.57 |
ROIC/WACCN/A
WACC7.04%
2.3 Liquidity
UPC has a Current Ratio of 1.63. This is a normal value and indicates that UPC is financially healthy and should not expect problems in meeting its short term obligations.
The Current ratio of UPC (1.63) is worse than 69.27% of its industry peers.
A Quick Ratio of 1.46 indicates that UPC should not have too much problems paying its short term obligations.
UPC has a worse Quick ratio (1.46) than 67.19% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.63 | ||
| Quick Ratio | 1.46 |
3. Growth
3.1 Past
The earnings per share for UPC have decreased strongly by -65.07% in the last year.
Looking at the last year, UPC shows a very negative growth in Revenue. The Revenue has decreased by -22.32% in the last year.
UPC shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 2.53% yearly.
EPS 1Y (TTM)-65.07%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-1720.73%
Revenue 1Y (TTM)-22.32%
Revenue growth 3Y1.72%
Revenue growth 5Y2.53%
Sales Q2Q%-30.23%
3.2 Future
No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
UPC reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A
5. Dividend
5.1 Amount
No dividends for UPC!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
UNIVERSE PHARMACEUTICALS INC
NASDAQ:UPC (11/18/2024, 6:51:44 PM)
2.15
+2.01 (+1428.07%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap50.85M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -37.53% | ||
| ROE | -69.36% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 28.27% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.54
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.08 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 1.63 | ||
| Quick Ratio | 1.46 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)-65.07%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next YN/A
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-22.32%
Revenue growth 3Y1.72%
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y